|
시장보고서
상품코드
2050533
항생제 시장 : 약제 클래스별, 항균 스펙트럼별, 투여 경로별, 용도별, 유통 채널별, 지역별Antibacterial Drugs Market, By Drug Class, By Spectrum of Activity, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
항생제 시장은 2026년에 492억 1,000만 달러로 추계되고 있어 2033년까지 687억 8,000만 달러에 이를 전망입니다. 2026-2033년까지 CAGR 4.9%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 492억 1,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년까지 예측 기간 CAGR : | 4.90% | 2033년 금액 예측 : | 687억 8,000만 달러 |
항생제(항균제라고도 함)는 세균 감염과 싸우는 의약품으로 세균을 사멸시키거나 증식을 억제하는 방식으로 작용합니다. 이들은 폐렴, 결핵, 탄저병, 매독, 나병, 리스테리아증 등 다양한 감염성 질환의 치료에 널리 사용되고 있습니다. 감염성 질환의 확산, 제약사들의 항생제 연구 투자 증가, 강력한 신약 개발 파이프라인 등의 요인이 예측 기간 동안 시장 성장을 견인할 것으로 예측됩니다. 그러나 신규 항생제 승인에 대한 정부의 엄격한 규제와 약제 내성균의 발생은 시장 성장을 어느 정도 억제할 가능성이 있습니다.
시장 역학
세균성 감염증의 유병률 증가, 신제품 출시, 강력한 파이프라인 의약품 등의 주요 요인이 예측 기간 동안 세계 항생제 시장을 견인할 것으로 예측됩니다. 미국 질병예방통제센터(CDC)에 따르면, 2021년에만 미국에서 280만 건 이상의 항생제 내성 감염이 발생했고, 35,000명 이상이 사망했습니다. 이로 인해 효과적인 항생제에 대한 수요가 크게 증가하고 있습니다. 또한, 주요 기업들은 혁신적인 의약품을 개발하기 위해 지속적으로 연구개발에 집중하고 있습니다. 예를 들어, 2022년 8월 Pfizer Inc. 는 복잡한 요로감염 및 복강내 감염 치료제로서 새로운 항생제 '레레박탐'에 대해 미국 식품의약국(USFDA)의 승인을 획득했습니다. 그러나 신규 항생제 승인에 대한 엄격한 규제와 항생제 내성 증가 등의 요인이 시장 성장을 억제할 것으로 예측됩니다. 또한, 박테리오파지 치료와 같은 대체 치료법 개발에 집중하는 것은 향후 몇 년 동안 유망한 비즈니스 기회를 가져올 것으로 예측됩니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 이 보고서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 항생제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 항생제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 항생제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 항생제 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 항생제 시장 : 항균 스펙트럼별, 2021-2033년
제6장 세계의 항생제 시장 : 투여 경로별, 2021-2033년
제7장 세계의 항생제 시장 : 용도별, 2021-2033년
제8장 세계의 항생제 시장 : 유통 채널별, 2021-2033년
제9장 세계의 항생제 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌 및 조사 방법
JHS 26.06.15Antibacterial Drugs Market is estimated to be valued at USD 49.21 Bn in 2026 and is expected to reach USD 68.78 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 49.21 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.90% | 2033 Value Projection: | USD 68.78 Bn |
Antibacterial drugs, also known as antibiotics, are medicines that fight bacterial infections and work by either killing or inhibiting the growth of bacteria. They are widely used for the treatment of various infections such as pneumonia, tuberculosis, anthrax, syphilis, leprosy, and listeriosis. Factors such as growth in the prevalence of infectious diseases, increasing investment by pharmaceutical companies in antibiotic research, and strong pipeline of newly developed drugs are expected to drive the market growth during the forecast period. However, stringent government regulations for the approval of new antibiotics and antibiotic resistance development may restrain the market growth to a certain extent.
Market Dynamics
Key factors, such as increasing prevalence of bacterial infections, new product launches, and strong pipeline drugs, are projected to drive the global antibacterial drugs market during the forecast period. As per Centers for Disease Control and Prevention (CDC), in 2021 alone over 2.8 million antibiotic-resistant infections occurred in the U.S. and more than 35,000 people died. This creates significant demand for effective antibacterial drugs. Furthermore, large players are continuously focusing on R&D to develop innovative drugs. For instance, in August 2022, Pfizer Inc. received USFDA approval for its new antibiotic treatment, relebactam, to treat complicated urinary tract and intra-abdominal infections. However, factors like stringent regulations for approval of new antibiotics and increasing antibiotic resistance development are anticipated to restrain the market growth. Moreover, focus on the development of alternative treatment methods like bacteriophage therapy is expected to present lucrative opportunities in the coming years.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antibacterial drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer, Abbott, Merck, GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb Company, Johnson & Johnson, Sanofi, Bayer, and Novartis
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antibacterial drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibacterial drugs market
Market Segmentation
- By Drug Class Insights (Revenue, USD Billion, 2021 - 2033)
- Penicillins
- Cephalosporins
- Aminoglycosides
- Tetracyclines
- Macrolides
- Fluoroquinolones
- Sulfonamides
- Others
- By Spectrum of Activity Insights (Revenue, USD Billion, 2021 - 2033)
- Broad-spectrum Antibiotics
- Narrow-spectrum Antibiotics
- By Route of Administration Insights (Revenue, USD Billion, 2021 - 2033)
- Oral
- Topical
- Intravenous
- Other Routes
- By Application Insights (Revenue, USD Billion, 2021 - 2033)
- Skin Infections
- Respiratory Infections
- Urinary Tract Infections
- Septicemia
- Ear Infections
- Gastrointestinal Infections
- Other Applications
- By Distribution Channel Insights (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Regional Insights (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Merck & Co., Inc.
- Abbott Laboratories
- Novartis International AG
- GlaxoSmithKline plc
- Sanofi
- Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Astellas Pharma Inc.
- Johnson & Johnson
- Amgen Inc.
- Bayer AG
- Eli Lilly and Company
- AstraZeneca plc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Antibacterial Drugs Market, By Drug Class
- Global Antibacterial Drugs Market, By Spectrum of Activity
- Global Antibacterial Drugs Market, By Route of Administration
- Global Antibacterial Drugs Market, By Application
- Global Antibacterial Drugs Market, By Distribution Channel
- Global Antibacterial Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Antibacterial Drugs Market, By Drug Class, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Penicillins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Cephalosporins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Aminoglycosides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Tetracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Macrolides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Fluoroquinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Sulfonamides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
5. Global Antibacterial Drugs Market, By Spectrum of Activity, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Broad-spectrum Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Narrow-spectrum Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
6. Global Antibacterial Drugs Market, By Route of Administration 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Other Routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
7. Global Antibacterial Drugs Market, By Application, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Skin Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Respiratory Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Urinary Tract Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Septicemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Ear Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Gastrointestinal Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Other Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
8. Global Antibacterial Drugs Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
9. Global Antibacterial Drugs Market, By Region, 2021 - 2033, Value (USD Billion)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Billion)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Billion)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Spectrum of Activity, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Spectrum of Activity, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Spectrum of Activity, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Spectrum of Activity, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Spectrum of Activity, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Spectrum of Activity, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Billion)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
